The parallel increase in inflammation marker TNF-α, along with AmotL2 expression in EGCs, varying from low TNF-α/medium AmotL2 signal in controls to high TNF-α/high AmotL2 after treatment (Figure 5), are interesting evidence that might indicate the involvement of EGCs in inflammatory bowel disease [46]. This evidence concerns the gene AMOTL2 and inflammatory bowel disease.